Japan Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Buy Report

Published: June 23, 2025 Report Code: GDME25619CCDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData’s “Japan Oncology Market Outlook to 2033” is a comprehensive databook report, covering key market data on the Japan Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The Japan Oncology Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2024 company share data for Oncology Market.
• Global corporate-level profiles of key companies operating within the Japan Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

Japan Oncology is segmented as follows – _x000D_

• Colorectal Cancer Screening Tests_x000D_

• EGFR Tests_x000D_

• KRAS Tests_x000D_

• HER2 Tests_x000D_

• BRCA Tests_x000D_

• ALK Tests_x000D_

• BRAF Tests_x000D_

• BCR-ABL Tests_x000D_

• PD-L1 Tests

Reasons to Buy

The Japan Oncology Market report helps you to develop –

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Abbott Laboratories

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 5

2 Introduction 6

2.1 What Is This Report About? 6

2.2 Oncology Market Segmentation 6

2.3 Definitions of Markets Covered in the Report 8

3 Oncology Market, Japan 15

3.1 Oncology Market, Japan, Revenue ($m), 2018-2033 15

3.1.1 ALK Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 18

3.1.2 BCR-ABL Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 20

3.1.3 BRAF Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 22

3.1.4 BRCA Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 24

3.1.5 Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 26

3.1.6 EGFR Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 28

3.1.7 HER2 Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 30

3.1.8 KRAS Tests Market, Japan, Revenue ($m), by Segment, 2018-2033 32

3.2 Oncology Market, Japan, Volume (Units), 2018-2033 34

3.2.1 ALK Tests Market, Japan, Volume (Units), by Segment, 2018-2033 37

3.2.2 BCR-ABL Tests Market, Japan, Volume (Units), by Segment, 2018-2033 39

3.2.3 BRAF Tests Market, Japan, Volume (Units), by Segment, 2018-2033 41

3.2.4 BRCA Tests Market, Japan, Volume (Units), by Segment, 2018-2033 43

3.2.5 Colorectal Cancer Screening Tests Market, Japan, Volume (Units), by Segment, 2018-2033 45

3.2.6 EGFR Tests Market, Japan, Volume (Units), by Segment, 2018-2033 48

3.2.7 HER2 Tests Market, Japan, Volume (Units), by Segment, 2018-2033 50

3.2.8 KRAS Tests Market, Japan, Volume (Units), by Segment, 2018-2033 52

3.3 Oncology Market, Japan, Average Price ($) , 2018-2033 54

3.4 Oncology Market, Japan, Company Share by Revenue ($m), 2024 57

4 Overview of Key Companies in Japan, Oncology Market 59

4.1 F. Hoffmann-La Roche Ltd 59

4.1.1 Company Overview 59

4.2 Agilent Technologies Inc 59

4.2.1 Company Overview 59

4.3 Abbott Laboratories 59

4.3.1 Company Overview 59

4.4 BioGenex Laboratories Inc 59

4.4.1 Company Overview 59

4.5 Danaher Corp 60

4.5.1 Company Overview 60

4.6 Amoy Diagnostics Co Ltd 60

4.6.1 Company Overview 60

4.7 Alfresa Pharma Corp 60

4.7.1 Company Overview 60

4.8 Qiagen NV 60

4.8.1 Company Overview 60

4.9 Eiken Chemical Co Ltd 61

4.9.1 Company Overview 61

4.10 SENTINEL CH SpA 61

4.10.1 Company Overview 61

5 Oncology Market Pipeline Products 62

6 Financial Deals Landscape 127

6.1 Debt Offerings 127

6.1.1 Astellas Pharma Prices USD545.6 Million in Public Offering of

0.87% Series 5 Unsecured Bonds Due 2029 127

6.1.2 Astellas Pharma Prices USD136.4 Million in Public Offering of

1.038% Series 6 Unsecured Bonds Due 2031 128

6.2 Venture Financing 129

6.2.1 The IT Lab Secures Venture Financing 129

7 Recent Developments 130

7.1 Corporate Communications 130

7.1.1 Apr 07, 2025: Ono Pharmaceutical Makes Changes of Board of Directors and Corporate Officers 130

7.1.2 Aug 23, 2024: Caris Life Sciences Announces Appointment of Dave Fredrickson to Board of Directors 130

7.2 Financial Announcements 131

7.2.1 May 08, 2025: Ono Pharmaceutical Reports Results for Fiscal Year Ended March 31, 2025 131

7.2.2 Nov 08, 2024: Human Metabolome Announces Consolidated Financial Results for the First Quarter of Fiscal Year Ending June 30, 2025 131

7.2.3 Aug 01, 2024: Astellas Pharma Announces Financial Results for Q1 FY2024 131

7.3 Government and Public Interest 132

7.3.1 May 08, 2025: Number of Patients Registered for Cancer Gene Panel Testing Under Health Insurance Coverage Reaches 100,000 132

7.4 Other Significant Developments 133

7.4.1 Feb 21, 2025: The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research 133

7.5 Product News 134

7.5.1 Nov 07, 2024: Nec and Nec Bio Publish Foundational Work on T Cell Receptor Engineering Using Proprietary Generative AI at the Society for Immunotherapy of Cancer Annual Meeting 134

7.5.2 Nov 05, 2024: National Cancer Center, Premia, and Paradigm Launch Treatment Development Platform “LC-SCRUM-CD'' 134

7.5.3 Sep 26, 2024: Takara Bio Europe Unveils New Large-Scale NGS Profiling System and Chemistries 135

7.5.4 Sep 24, 2024: Industry-Academia Collaboration Nationwide Cancer Genome Screening SCRUM-Japan Launches Fifth Project 135

7.5.5 Sep 20, 2024: Approval for Manufacturing and Marketing of “Hemcyte®,” Japan’s First Gene Panel Test for Hematopoietic Tumors 138

7.5.6 Sep 17, 2024: Liquid Biopsy Confirmed to Be Useful in Deciding on Adjuvant Therapy After Surgery for Colorectal Cancer Liver Metastases 139

7.5.7 Sep 17, 2024: Scrum-Japan Gozila Project: Large-Scale Study of Over 4,000 Cases Confirms Extension of Survival Time Through Personalized Cancer Medicine 140

7.5.8 Aug 01, 2024: Development of a Method to Predict Onset of Non-Alcoholic Fatty Liver Disease —Contributing to Preventive Healthcare for Lifestyle Diseases 141

7.5.9 Jul 08, 2024: Noninvasive Urine Test for Early Detection of Cervical Cancer Virus Proteins 141

7.6 Strategy And Business Planning 142

7.6.1 Apr 28, 2025: PredxBio and Hamamatsu Photonics Announce Strategic Partnership to Deliver Next-Generation Spatial Biology Solutions for Cancer Research and Therapeutic Development 142

7.6.2 Apr 15, 2025: BCAN Announces Partnerships With Ferring Pharmaceuticals and Astellas/Pfizer Alliance 143

7.6.3 Apr 14, 2025: JelloX Biotech Establishes US Research Base 144

7.6.4 Jul 01, 2024: NURA Health Screening Center Opens in Hanoi, Vietnam 144

8 Appendix 145

8.1 Research Methodology 146

8.1.1 Coverage 146

8.1.2 Secondary Research 146

8.1.3 Primary Research 146

8.1.4 Market Modeling and Forecasting 147

8.1.5 Company Share Analysis 148

8.1.6 Benchmarking 149

8.2 GlobalData Consulting 150

8.3 Contact Us 150

8.4 Disclaimer 150

Table

Table 1: Oncology Market, Japan, Revenue ($m), USD Constant, 2018-2033 16

Table 2: ALK Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 19

Table 3: BCR-ABL Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 21

Table 4: BRAF Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 23

Table 5: BRCA Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 25

Table 6: Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 27

Table 7: EGFR Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 29

Table 8: HER2 Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 31

Table 9: KRAS Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 33

Table 10: Oncology Market, Japan, Volume (Units), 2018-2033 35

Table 11: ALK Tests Market, Japan, Volume (Units), 2018-2033 38

Table 12: BCR-ABL Tests Market, Japan, Volume (Units), 2018-2033 40

Table 13: BRAF Tests Market, Japan, Volume (Units), 2018-2033 42

Table 14: BRCA Tests Market, Japan, Volume (Units), 2018-2033 44

Table 15: Colorectal Cancer Screening Tests Market, Japan, Volume (Units), 2018-2033 46

Table 16: EGFR Tests Market, Japan, Volume (Units), 2018-2033 49

Table 17: HER2 Tests Market, Japan, Volume (Units), 2018-2033 51

Table 18: KRAS Tests Market, Japan, Volume (Units), 2018-2033 53

Table 19: Oncology Market, Japan, Average Price ($), 2018-2033 54

Table 20: Oncology Market, Japan, Company Share by Revenue ($m), 2024 58

Table 21: Oncology Market Pipeline Products 62

Table 22: Astellas Pharma Prices USD545.6 Million in Public Offering of 0.87% Series 5 Unsecured Bonds Due 2029 127

Table 23: Astellas Pharma Prices USD136.4 Million in Public Offering of 1.038% Series 6 Unsecured Bonds Due 2031 128

Table 24: The IT Lab Secures Venture Financing 129

Table 25: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 147

Figures

Figure 1: Oncology Market, Japan, Revenue ($m), USD Constant, 2018-2033 15

Figure 2: ALK Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 18

Figure 3: BCR-ABL Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 20

Figure 4: BRAF Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 22

Figure 5: BRCA Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 24

Figure 6: Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 26

Figure 7: EGFR Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 28

Figure 8: HER2 Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 30

Figure 9: KRAS Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033 32

Figure 10: Oncology Market, Japan, Volume (Units), 2018-2033 34

Figure 11: ALK Tests Market, Japan, Volume (Units), 2018-2033 37

Figure 12: BCR-ABL Tests Market, Japan, Volume (Units), 2018-2033 39

Figure 13: BRAF Tests Market, Japan, Volume (Units), 2018-2033 41

Figure 14: BRCA Tests Market, Japan, Volume (Units), 2018-2033 43

Figure 15: Colorectal Cancer Screening Tests Market, Japan, Volume (Units), 2018-2033 45

Figure 16: EGFR Tests Market, Japan, Volume (Units), 2018-2033 48

Figure 17: HER2 Tests Market, Japan, Volume (Units), 2018-2033 50

Figure 18: KRAS Tests Market, Japan, Volume (Units), 2018-2033 52

Figure 19: Oncology Market, Japan, Company Share (%), 2024 57

Japan Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others standard reports

Currency USD

Single User

$4,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports

Medical Devices

New

Global M&A Deals in H1 2026 - Top Themes by…

Medical Devices

New

Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…

Medical Devices

New

AI-designed Materials: Market Trends and Innovations

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Japan Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others in real time.

Access a live Japan Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Japan Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports